Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Bevacizumab + Second-line Chemotherapy in Advanced Triple-negative Breast Cancer (Observational)
ChiCTR2600117817Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab and bevacizumab in breast cancer, sponsored by Henan Cancer Hospital. Primary endpoint: Progression-Free Survival (PFS) assessed per RECIST v1.1. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600117817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117817.